Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

Thomann, Robert; Zechmann, Stefan; Alexander-David, Nicola; Jornayvaz, François

doi:10.2147/DMSO.S252667

Scientific article

English

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

ContributorsThomann, Robert; Zechmann, Stefan; Alexander-David, Nicola; Jornayvaz, François

Published inDiabetes, Metabolic Syndrome and Obesity, vol. 13, p. 2359-2365

Publication date2020

Abstract

Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.

Keywords

Switzerland
Insulin glargine 300 U/mL
Real-world
Type 2 diabetes

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

MASLD/MASH et résistance à l'insuline (997)

Citation (ISO format)

THOMANN, Robert et al. Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland. In: Diabetes, Metabolic Syndrome and Obesity, 2020, vol. 13, p. 2359–2365. doi: 10.2147/DMSO.S252667

Article (Published version)

CC BY-NC

Identifiers

PID : unige:143198
DOI : 10.2147/DMSO.S252667
PMID : 32753920

Additional URL for this publicationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342388/

Journal ISSN1178-7007

305views

219downloads

Creation07/08/2020 08:24:00

First validation07/08/2020 08:24:00

Update06/01/2025 08:26:53

Status update06/01/2025 08:26:53

Last indexation06/01/2025 08:29:05

Archive ouverte UNIGE

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland

Insulin glargine 300 U/mL (Gla-300; Toujeo®) is a second-generation once-daily basal insulin. Previous randomized controlled trials showed comparable HbA1c reductions with lower rates of hypoglycemia of Gla-300 versus Gla-100.

Technical informations